Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study

Table 2 Distribution of responders across the treatment arms (double-blind core study)

	Placebo	Mavoglurant			Total
	Placebo	25 mg	50 mg	100 mg	Total
Total number of patients (N)^a	42	31	27	39	139
Number of patients who completed 12 weeks of treatment	40	31	27	37	135
Number of responders (observed number of patients who responded)	8	4	8	8	28
Expected number of responders^b (if distribution of response would have been random)	8.5	6.2	5.4	7.9	28

^aOnly data from 134 patients queried for CGI improvement
^bUnder the assumption of no treatment effect, i.e., identical response chance for each patient

ISSN: 1866-1955